Abstract
The use of imatinib, second and third generation ABL tyrosine kinase inhibitors (TKI) (i.e. dasatinib, nilotinib, bosutinib and ponatinib) made CML a clinically manageable and, in a small percentage of cases, a cured disease. TKI therapy also turned CML blastic transformation into a rare event; however, disease progression still occurs in those patients who are refractory, not compliant with TKI therapy or develop resistance to multiple TKIs. In the past few years, it became clear that the BCRABL1 oncogene does not operate alone to drive disease emergence, maintenance and progression. Indeed, it seems that bone marrow (BM) microenvironment-generated signals and cell autonomous BCRABL1 kinase-independent genetic and epigenetic alterations all contribute to: i. persistence of a quiescent leukemic stem cell (LSC) reservoir, ii. innate or acquired resistance to TKIs, and iii. progression into the fatal blast crisis stage. Herein, we review the intricate leukemic network in which aberrant, but finely tuned, survival, mitogenic and self-renewal signals are generated by leukemic progenitors, stromal cells, immune cells and metabolic microenvironmental conditions (e.g. hypoxia) to promote LSC maintenance and blastic transformation.
Keywords: Stem cells, microenvironment, chronic myeloid leukemia, hematopoietic stem cell.
Current Drug Targets
Title:Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Volume: 18 Issue: 4
Author(s): Danilo Perrotti, Giovannino Silvestri, Lorenzo Stramucci, Justine Yu and Rossana Trotta
Affiliation:
Keywords: Stem cells, microenvironment, chronic myeloid leukemia, hematopoietic stem cell.
Abstract: The use of imatinib, second and third generation ABL tyrosine kinase inhibitors (TKI) (i.e. dasatinib, nilotinib, bosutinib and ponatinib) made CML a clinically manageable and, in a small percentage of cases, a cured disease. TKI therapy also turned CML blastic transformation into a rare event; however, disease progression still occurs in those patients who are refractory, not compliant with TKI therapy or develop resistance to multiple TKIs. In the past few years, it became clear that the BCRABL1 oncogene does not operate alone to drive disease emergence, maintenance and progression. Indeed, it seems that bone marrow (BM) microenvironment-generated signals and cell autonomous BCRABL1 kinase-independent genetic and epigenetic alterations all contribute to: i. persistence of a quiescent leukemic stem cell (LSC) reservoir, ii. innate or acquired resistance to TKIs, and iii. progression into the fatal blast crisis stage. Herein, we review the intricate leukemic network in which aberrant, but finely tuned, survival, mitogenic and self-renewal signals are generated by leukemic progenitors, stromal cells, immune cells and metabolic microenvironmental conditions (e.g. hypoxia) to promote LSC maintenance and blastic transformation.
Export Options
About this article
Cite this article as:
Perrotti Danilo, Silvestri Giovannino, Stramucci Lorenzo, Yu Justine and Trotta Rossana, Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160615074120
DOI https://dx.doi.org/10.2174/1389450117666160615074120 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Recent Patents on Biotechnology Preparation of Therapeutic Dose of <sup>177</sup>Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy
Current Radiopharmaceuticals Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Genetic Variation of Human Adrenergic Receptors: From Molecular and Functional Properties to Clinical and Pharmacogenetic Implications
Current Topics in Medicinal Chemistry Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Efficacy of Enzyme Replacement Therapy in Fabry Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Human Apolipoprotein C-III – A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins
Cardiovascular & Hematological Disorders-Drug Targets Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications
Current Pharmaceutical Design Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry